Benjamin Demoss, MD
Advanced Heart Failure and Transplant Cardiology · Atlanta, GANPI 1356668081
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,463 of the $17,487 with a category attached, or 71.3%. Abbott accounts for 80.7% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $6,038 and has fallen 51.1% since, to $2,953 in 2025.
Across 210 payments — averaging $83.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$14K
- Cvrx, Inc.$595
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$431
- Medtronic$427
- Merck$300
- Novartis$276
- plus $1K from 28 others
What the payments were for
- Consulting fees$12,46371%
- Travel & lodging$10%
- Food & beverage$5,02329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 69 | $14,109 |
| Cvrx, Inc. | 28 | $595 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $431 |
| Medtronic | 4 | $427 |
| Merck | 16 | $300 |
| Novartis | 11 | $276 |
| Alnylam Pharmaceuticals Inc. | 10 | $255 |
| Boehringer Ingelheim | 12 | $224 |
| AstraZeneca | 7 | $147 |
| Pfizer | 7 | $128 |
| Edwards Lifesciences | 2 | $71 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Bayer | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Nuwellis, Inc. | 2 | $32 |
| Bridgebio Pharma, Inc. | 1 | $29 |
| Procyrion, Inc. | 1 | $29 |
| Amgen | 1 | $24 |
| Atricure, Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Phadia US Inc. | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
| Haemonetics Corporation | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Akcea Therapeutics, Inc. | 1 | $17 |
| Argon Medical Devices, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Heartflow, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Abiomed | 1 | $14 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$7,615
- CardioMEMS HF System$5,560
- MC3 NAUTILUS(TM) ECMO OXYGENATOR$212
- Penditure$196
- Barostim Neo System$125
- ENTRESTO$106
How this compares
$17,487 in reported general payments places this provider in the 60th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
See all advanced heart failure and transplant cardiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 126 | $142,004 |
| EliquisApixaban | 35 | $44,604 |
| JardianceEmpagliflozin | 28 | $36,766 |
| FarxigaDapagliflozin Propanediol | 25 | $21,432 |
| Sirolimus | 12 | $3,644 |
| Tacrolimus | 14 | $2,952 |
| Torsemide | 56 | $1,271 |
| Hydralazine Hcl | 37 | $678 |
| Spironolactone | 69 | $542 |
| Gentamicin Sulfate | 12 | $490 |
| Metoprolol Succinate | 34 | $463 |
| Carvedilol | 37 | $370 |
| Atorvastatin Calcium | 59 | $334 |
| Potassium Chloride | 19 | $261 |
| Bumetanide | 14 | $257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $276 | $142,004126 claims |
| PfizerEliquis | $128 | $44,60435 claims |
| Boehringer IngelheimJardiance | $224 | $36,76628 claims |
| AstraZenecaFarxiga | $147 | $21,43225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.
Other advanced heart failure and transplant cardiology in Atlanta
- Robert ColeAtlanta$213K
- Rahul LounganiAtlanta$51K
- Arun KrishnamoorthyAtlanta$37K
- Mehrdad ToosiAtlanta$15K
- Brenda HottAtlanta$8K
- Divya GuptaAtlanta$8K
- Kunal BhattAtlanta$6K
- Mahmoud AbdouAtlanta$4K
- Chad MaoAtlanta$3K
- Sonjoy LaskarAtlanta$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.